Clinical Trial Update: Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating proper dosing and safety of the oral FXIa inhibitor BAY 2433334 versus apixaban in patients with atrial fibrillation; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Apixaban (apixaban)
• BAY 2433334 (BAY 2433334)

Snippet

Sponsor: Bayer | Conditions: Atrial Fibrillation (AF) | Phase 2 | Status: COMPLETED | Results posted: 2022-10-27